Abstract. The present study aimed to investigate the protective effect of mesenchymal stem cell (MSC) therapy in combination with p38 mitogen-activated protein (MAPK) inhibition against myocardial infarction (MI) injury in rats, and to elucidate the underlying mechanisms. An MI model was established by ligation of the anterior descending branch of the left coronary artery. The rats were divided into four groups: MSC transplantation, p38MAPK inhibitor (SB203580), MSC + SB203580 and model control group. HE staining and a TUNEL assay were performed to evaluate pathological changes and apoptosis. The expression levels of p38MAPK and transforming growth factor β-activated kinase 1 (TAK1) were determined using reverse transcription-polymerase chain reaction and western blot analyses. As shown by HE staining, classical morphological changes, including irregular cell arrangement and inflammatory infiltration were observed in the model rats, whereas MSC therapy or injection of the p38MAPK inhibitor ameliorated these pathological changes. Of note, the combined application of MSCs with the p38MAPK inhibitor exerted additive effects. The TUNEL assay showed that the combined application of MSCs with p38MAPK inhibitor also led to potentiation of effects, compared with either MSCs therapy or p38MAPK inhibitor injection alone. Mechanistically, the combined application of MSCs with p38MAPK inhibitor decreased the expression levels of TAK1 and p38MAPK at the mRNA and protein levels. In conclusion, p38MAPK inhibition potentiated the protective effects of MSCs therapy against MI in rats.
Introduction
Myocardial infarction (MI) is caused by occlusion of the coronary artery, and is pathologically characterized by severe necrosis of cardiomyocytes due to persistent ischemia. MI is now a common disease affecting human health and coronary atherosclerosis is the major contributing factor for MI (1) . In addition, hypertension, diabetes and blood lipid abnormalities can also contribute to MI, and smoking and alcohol abuse may be important inducers of blood abnormalities (2) . Investigations using molecular methods have also suggested that the accumulation of reactive oxygen species stress, upregulation of adhesive molecules, and increases of serum homocysteine, blood fibrinogen and coagulation, may lead to abnormalities of blood lipids, resulting in MI (3) .
Coronary atherosclerosis is elicited by a variety of endogenous and exogenous factors through different intracellular signaling pathways (4) . MSC transplantation can promote angiogenesis in the infarct area to ameliorate cardiac function in MI (5) . However, the clinical application of MSC transplantation is restricted by low survival rates of MSCs following transplantation (6) . Several signaling pathways are abnormally regulated in the process of MI, including transforming growth factor-β (TGF-β)/small mothers against decapentaplegic, Janus kinase-signal transducers and activators of transcription, p38 mitogen-activated protein kinases (p38MAPK), phosphoinositide-3-kinase (PI3K)/Akt-endothelial nitric oxide synthase, PI3K/protein kinase C and Wnt (7) (8) (9) . Among these signaling pathways, p38MAPK is involved in regulating the inflammatory process. Tumor necrosis factor (TNF)-α and interleukin (IL)-6 are classical pro-inflammatory factors, which are modulated by the p38MAPK pathway (8) . The p38MAPK pathway is also important in cell differentiation and development (10) . p38MAPK functions through phosphorylating nuclear transcription factors and regulating gene expression. The inhibition of p38MAPK has been reported to protect against MI (4) . However, the effects of the inhibition of p38MAPK on MSC therapy in an MI model remain to be elucidated. In the present study, an MI model was established in rats by ligation of the left anterior descending branch of the coronary artery. The MI model was exposed to the combined application of p38MAPK inhibition and MSC transplantation. The aim was to provide novel evidence for MI therapy. /ml) were resuspended in low-glucose DMEM with 15% FBS (GE Healthcare Life Sciences), 100 U/ml penicillin and streptomycin at 37˚C and 5% CO 2 . The cells were distinguished using flow cytometry with antibodies against CD34 (1:100; cat. no. ab23830, Abcam, Shanghai, China), CD44 (1:100; cat. no. ab46793, Abcam) and CD105 (1:100; cat. no. ab53318; Abcam). The cell growth curve is shown in Fig. 1 .
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MI model establishment.
The specific pathogen-free rats (weight, 250±50 g) were purchased from the SLAC and raised in an animal room for at least 7 days prior to experiments. The acute MI model was established by ligating the anterior descending branch of the coronary artery. Following anesthesia via intraperitoneal injection of 40 mg/kg pentobarbital with 0.l mg/kg atropine, the rats were fixed on the bench in the supine position. A non-invasive method was used to insert a tube (18G) into the mouth in order to expose the throat. Positive pressure ventilation was applied using a ventilator to assist with animal breathing. The tidal volume was set at 9-12 ml and the breath rate was set at 1:1.5 with a frequency of 60/min. Following exposure of the heart, the anterior descending branch of the left coronary artery was identified and ligated using 5-0 silk. The ST elevation was determined upon ECG and the tissues downstream of the coronary artery ligation were white or purple in color. Expansion of the left atrial appendage was performed to determine successful modeling of the MI model. The MI rats were then randomly divided into four groups: MSC therapy group, P38MAPK inhibition group, MSC therapy with p38MAPK inhibition group and saline control group. Subsequently, MSCs (1.5x10 6 /100 µ1) and/or SB203580 (0.2 mg/kg) were injected twice each week for a consecutive 4-week period. HE staining and a TUNEL assay were then performed to determine the pathological changes and apoptosis.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The heart tissues were collected for RT-qPCR analysis. Total mRNA was isolated according to the manufacturer's protocol of the kit (cat. no. 74134; Qiagen, Inc., Valencia, CA, USA). The concentration and purity of the total RNA were determined using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.). Subsequently, the mRNAs underwent RT-qPCR combined with SYBR staining to amplify the expression (cat. no. RR430A; Takara Biotechnology Co., Ltd., Dalian, China). The primers were synthesized by Shanghai Sangon Biotech Co., Ltd. (Shanghai, China). The primers were as follows: p38MAPK, forward 5'-tcgagaccgtttcagtccat-3' and reverse 5'-cca cgg acc aaa tatcca ct-3'; transforming growth factor β-activated kinase 1 (TAK1), forward 5'-cca tcc caa tgg cgt atc tta c-3' and reverse 5'-tca tcc tgg tcc aat tct gca a-3'; GAPDH, forward 5'-act tga agg gtg gag cca aa-3' and reverse 5'-cca gga aa tga gct tga ca-3'. The Cq value for each gene was detected and the expression levels of target genes were calculated using the 2 -ΔΔCq method (12) . RT-qPCR was performed on a real-time PCR system (LightCycler 96; Roche Diagnostics, Basel, Switzerland) with the following procedure: Initial denaturation at 95˚C for 5 min, denaturation at 95˚C for 30 sec, annealing at 60˚C for 13 sec and extension at 72˚C for 30 sec, for 37 cycles. The reaction sample consisted of 10 µl 2X SYBR Fast qPCR mix, 0.8 µl forward/reverse primers (10 mΜ), 0.4 µl 50X ROX Reference Dye II and 2 µl cDNA template.
Western blot analysis. Myocardial tissues were collected for protein isolation (ReadyPrep; GE Healthcare Life Sciences). The protein concentrations were determined using a BCA protein assay kit (Thermo Fisher Scientific, Inc.). 25 µg proteins from each group were obtained for sodium dodecyl sulfate polyacrylamide gel electrophoresis (12%) and transferred onto nitrocellulose membranes for western blot analysis. The membranes were incubated with the following primary antibodies: p38MAPK (1:2,000; cat. no. sc-17852-R, Santa Cruz Biotechnology, Inc., Dallas, TX, USA), TAK1 (1:2,000; cat. no. sc-7967, Santa Cruz Biotechnology, Inc.) and actin (1:3,000; cat. no. sc-58673, Santa Cruz Biotechnology, Inc.). Following incubation with the primary antibodies at 4˚C overnight, the nitrocellulose membranes were washed three times and incubated with secondary antibody (HRP-labeled goat anti-rabbit IgG; cat. no. A16104SAMPLE, Thermo Fisher Scientific, Inc.) at 4˚C for 2 h. The staining of the blots was enhanced using an ECL kit (Thermo Fisher Scientific, Inc.). The densities of the blots were quantified using Quantity One software (v4.62; Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Statistical analyses.
Data are presented as the mean ± standard error of the mean. Statistical analyses were performed using one-way analysis of variance with GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Inhibition of p38MAPK potentiates the protective effect of MSC therapy against acute MI injury.
An acute MI model was produced using rats by ligating the anterior descending branch of the coronary artery. The modeling process is shown in Fig. 2A . During the present study, four rats died due to infection-induced heart failure. The ECG examination showed that the model rats exhibited acute anterior ST elevation ( Fig. 2B and C) . At 4 weeks post-treatment, the heart tissues were collected for HE staining. As shown in Fig. 3A , the cells in the model control group were loosely arranged with numerous bubbles, inflammatory cell infiltration and tissue injury. Following treatment with MSCs or SB203580, the cells were tightly arranged with few bubbles (Fig. 3B and C) . The combined application of MSCs with SB203580 exhibited optimal effects (Fig. 3D) . A TUNEL assay was also performed to detect apoptosis. Apoptotic cells in the control group were apparent (Fig. 4A ). Following treatment with MSCs or SB203580, the number of apoptotic cells was significantly decreased (Fig. 4B and C) . Consistent with the HE staining, the combined application of MSCs with SB203580 (Fig. 4D) showed optimal effects in decreasing apoptosis.
Inhibition of p38MAPK and MSC therapy functions through the p38MAPK-TAK1 pathway. mRNA and proteins were isolated to examine the underlying mechanisms. The expression levels of p38MAPK and TAK1 were determined. Compared with the control group, MSC therapy or SB203580 injection significantly decreased the expression of p38MAPK at the mRNA (Fig. 5A) and protein (Fig. 5B ) levels. In addition, the combined application of MSC therapy with SB203580 led to a further decrease in the expression of p38MAPK. The expression of TAK1 was also detected, which is upstream of the p38MAPK signaling pathway in the different groups. A consistent trend was observed in the groups as shown for p38MAPK ( Fig. 5A and B) .
Discussion
The MAPK family is a family of serine/threonine protein kinases, which can transfer signal transduction from the extracellular environment to the nucleus through the conservative three-cascade reaction (MAPKKK-MAPKK-MAPK) (13) . There are four classical MAPK signaling pathways, including the extracellular signal-regulated kinase (ERK) signaling pathway, c-Jun N-terminal kinase/stress-activated protein kinase, p38 MAPK signaling pathway and the ERK5/big MAPK 1 signaling pathway. These signaling pathways have functions in several biological processes, including regulating cell migration, apoptosis, differentiation and proliferation (14) . In the present study, it was found that the p38MAPK signaling pathway was critical in potentiating MSC therapy in MI injury.
The p38MAPK signaling pathway is one of the MAPK pathways, which can be activated by stress, cytokine stimulation, insulin and growth factor stimulation. In normal immune and inflammatory reactiona, the p38MAPK signaling pathway is activated to phosphorylate transcription factors and regulate gene expression, being involved in a variety of intracellular biological activities (15) . Upstream of the p38MAPK signal transduction pathway, TAK1 regulates the phosphorylation of p38MAPK through the activation of TGF-β. Therefore, the expression or activation of TAK1 is an important indicator of the activity of the TGF-β-TAK1-p38MAPK signaling pathway. Several studies have suggested that the p38MAPK pathway is activated in the MI model (5, 16) and p38MAPK has become a therapeutic target for heart diseases (17, 18) . However, other studies have demonstrated the pro-survival function of p38MAPK in MI (19, 20) . In the present study, it was demonstrated that the inhibition of p38MAPK alone ameliorated the injury induced by MI. The expression of p38MAPK was also decreased following treatment with p38MAPK inhibitor. The inhibition of p38MAPK potentiated the protective effect of MSC therapy in MI.
Acute coronary artery occlusion causes blood flow interruption and leads to necrosis of heart tissue. Following MI, inflammatory cell infiltration, and serum levels of IL-6 and TNF-α are upregulated, suggesting that inflammation is closely associated with MI (21, 22) . In the present study, ligation of the left coronary anterior descending branch was performed to produce MI, and the MI model was confirmed by ST elevation and pathological changes. This animal model is widely used to examine the mechanisms and enable screening of therapeutic agents. In the present study, the MI model was treated with p38MAPK inhibitor and/or MSCs twice each week for 4 weeks. MSCs are a type of non-hematopoietic stem cell found in bone marrow, which has the potential to differentiate into osteoblasts, fibroblasts, reticular cells, fat cells and endothelial cells. MSCs are characterized by their abundance, biodegradability and regeneration (22, 23) . Previously, MSC therapy has been used in the treatment of several diseases, including acute MI (24) . In the present study, a Percoll lymphocyte separating system was applied to obtain MSCs. This separation system has the advantage of obtaining high purity MSCs. In the present study, the MI rats were randomly divided into four groups. Following MSC therapy or injection with the p38MAPK inhibitor, the pathological changes observed in the heart tissue were ameliorated. In addition, the combined application of MSCs with the p38MAPK inhibitor showed additive effects. The ameliorative effects were reflected by a decrease in inflammation and morphological changes. The results of the TUNEL assay also indicated that that number of apoptotic cells following MI was significantly attenuated by MSC therapy or the inhibition of p38MAPK.
In conclusion, the present study evaluated the effects of inhibiting p38MAPK on MSC therapy against MI injury. Although the inhibition of p38MAPK or MSC therapy alone exerted mild protective effects, their combined application had a superior effect. These findings provide novel implications for the clinical application of MSC therapy for MI.
